A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses

A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses

Purpose: Single agent PD-1 inhibitors have yielded durable responses in a minority of gastroesophageal cancers. Radiation therapy has been recognized to promote antitumor immune responses and may synergize with anti-PD-1 agents. We sought to evaluate if combining palliative radiation therapy with pe...

Full description

Bibliographic Details
Main Authors: Joseph Chao, MD, Ting-Fang He, PhD, Massimo D'Apuzzo, MD, PhD, Yi-Jen Chen, MD, PhD, Paul Frankel, PhD, Michael Tajon, PhD, Helen Chen, MD, Shawn Solomon, BS, Samuel J. Klempner, MD, Marwan Fakih, MD, Peter Lee, MD
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109421001652

Internet

http://www.sciencedirect.com/science/article/pii/S2452109421001652

Similar Items